These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 3539322)

  • 21. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
    Kuppen PJ; Schuitemaker H; van 't Veer LJ; de Bruijn EA; van Oosterom AT; Schrier PI
    Cancer Res; 1988 Jun; 48(12):3355-9. PubMed ID: 2897238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
    Nicolson MC; Orr RM; O'Neill CF; Harrap KR
    Neoplasma; 1992; 39(3):189-95. PubMed ID: 1528325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies of interaction of trichloro{eta2-cis-N,N-dimethyl-1-[6-(N',N'-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin.
    Gay M; Montaña AM; Moreno V; Prieto MJ; Pérez JM; Alonso C
    Bioorg Med Chem; 2006 Mar; 14(5):1565-72. PubMed ID: 16256352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
    Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
    Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
    Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
    Ara G; Kusumoto T; Korbut TT; Cullere-Luengo F; Teicher BA
    Cancer Res; 1994 Mar; 54(6):1497-502. PubMed ID: 8137254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
    Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
    Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
    Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
    Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
    Masuda H; Tanaka T; Matsuda H; Kusaba I
    Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
    Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF
    Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.